AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03996668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thigh High Compression Stockings
Description: Thigh high compression stockings will be placed after induction of anesthesia and intubation.
Study NCT01344239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limb remote ischemic preconditioning(LRIP)
Description: LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
Study NCT03464084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Capsules containing microcrystalline cellulose
Study NCT03464084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: melatonin
Description: 5 mg of melatonin per os.
Study NCT03464084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bright light
Description: room light will be bright
Study NCT03464084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dim light
Description: room light will be dim
Study NCT03336931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular profiling and drug testing
Description: 1. Laboratory analysis including:~   A. Tumour molecular profiling: targeted whole exon variant analysis, whole genome (DNA) and transcriptome (RNA) sequencing, methylation analysis, proteomics analysis, immunohistochemistry B. In vitro high-throughput drug sensitivity testing C. In vivo drug testing using patient-derived xenograft (PDX) models D. Liquid biopsies~2. Multi-disciplinary Tumour Board case discussion~3. Recommendation of personalised therapy
Study NCT00006029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Study NCT00006029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00006029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated liposomal doxorubicin hydrochloride
Study NCT02986763 — intervention group
Intervention type: BIOLOGICAL
Intervention: Questionnaire, blood, urine, hair and dust samplings
Study NCT03967249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS GHR-LRx
Description: Participants will receive IONIS GHR-LRx by subcutaneous injection.
Study NCT03967249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin Receptor Ligand (SRL)
Description: Participants will receive Somatostatin Receptor Ligand (lanreotide, octreotide) once monthly.
Study NCT00006029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Study NCT00006029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine tartrate
Study NCT00006029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study NCT04612985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XACT Robotic System
Description: CT-guided Minimally Invasive Procedures e.g., Biopsies
Study NCT03076996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online support group
Description: Participants will be enrolled to form five groups of 8 to 10 participants, and then participants will participate in the 6 sessions of the structured educational and group counseling curriculum through the online platform.~The m/eHealth intervention components include:~* Informational messages that reflect the content of the structured group counseling curriculum, Positive Connections, and are posted to the group wall on a regular basis~* Moderated, closed group chats where ALHIV can interact with their peers and with a trained health counselor on a biweekly basis~* Access to a trained counselor via Facebook Messenger (during normal business hours) for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed
Study NCT02949882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yakult
Description: Containing at least 6,5\*10\^9 colony forming units (cfu) of Lactobacillus casei Shirota (LcS)
Study NCT02949882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy Peach Drink (AH Basic)
Description: Commercially available dairy drink with peach flavour.
Study NCT03153800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bronchial basal cells
Description: Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.
Study NCT01001520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolcapone
Description: Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period.
Study NCT01001520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period.
Study NCT03146338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium-rich mineral water (Rozana)
Description: intakes of 1.5 L by day
Study NCT00536510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: laropiprant/niacin (MK0524A)
Description: Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization
Study NCT00536510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization.
Study NCT02033044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive remediation
Description: Cognitive Rehabilitation (CR). Consisted on group sessions (5 individuals per group) of 120-minutes, twice a week during a total period of 16 weeks (32 sessions). The exercises addressed neurocognitive issues related to sustained attention, processing speed, memory and executive functioning. The whole program aimed at getting new strategies to improve functional adaptation, thus tasks were carried out in the clinical setting and at home. Some homework tasks were based on their daily life difficulties and problems. The main objective of this program was the generalization of rehabilitated cognitive functions to daily life activities. Most of the techniques were based on a previous program for bipolar disorder.
Study NCT02033044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation (PE). The psychoeducation intervention consisted of 16 weekly group sessions of 5 individuals of 120 minutes each (16 sessions). This therapy aimed at improving illness' consciousness , interpersonal abilities, family balance, therapeutical adherence, emotional management in frustrating situations, problems resolutions, and lifestyle regularity. On this intervention, no homework tasks were required. This intervention was based on the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program therapy.
Study NCT00767221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 8 mg PL-56 once daily for six months
Study NCT05929742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality training
Description: The experimental group received five additional days of supervised VR training using a wireless sensor in a private room in the neurological care ward.
Study NCT05929742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: early rehabilitation
Description: Five 60-minute sessions per week, was prescribed by a rehabilitation physician and performed by physical, occupational, and speech therapists from 3 to 6 days after admission.
Study NCT00465686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)
Description: ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions
Study NCT00465686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ergonomic desk and chair (Q-Learn Desk)
Description: child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
Study NCT01490281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: water-based exercise
Description: Interventions will consist of aerobic, muscular strength and flexibility exercises in the water
Study NCT01490281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: land-based exercise intervention
Description: Interventions will consist of aerobic, muscular strength and flexibility exercises in the land
Study NCT00404274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant (GW679769) oral tablets
Description: Casopitant will be available in the dose strength of 20,30 or 50 mg
Study NCT00404274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin oral tablets
Description: Warfarin will be available in the dose strength of 5 mg
Study NCT03093454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender Essential Oil
Description: Lavender essential oil will be applied topically and by inhalation to the lavender group.
Study NCT01127542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.
Study NCT01908127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: tell- show- do
Description: Children came in the operation room. Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant to increase their familiarity with dental procedures. The duration of the appointment was about 20 minutes and constant for all children.
Study NCT01908127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: film modelling
Description: the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
Study NCT01908127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of local anesthesia solution
Description: A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
Study NCT01908127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of local anesthesia solution
Description: A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
Study NCT01908127 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occlusal cavity preparation
Description: the occlusal cavity was prepared for pulpotomy and restoration of the teeth
Study NCT01908127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: occlusal cavity preparation
Description: the occlusal cavity was prepared for pulpotomy and restoration of the teeth
Study NCT01545635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate
Description: Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10\<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min~Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT >90sec and FIBTEM A10>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min~FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.~Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min
Study NCT01545635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma blood type 0, A, B and AB
Description: Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 \<7mm and/or ExTEM CT>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
Study NCT03258359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PACTN
Description: To treat patients with MDS who have failed treatment with hypomethylating agents or have relapsed after treatment with hypomethylating agents or have declined hypomethylating therapy.
Study NCT04165681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limbix Spark
Description: 5-week, self-guided mobile + VR CBT-based program for adolescent depression
Study NCT01127581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVI 200
Description: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study NCT01127581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone Vaginal Insert (DVI)
Description: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study NCT01439893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhNRG-1
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Study NCT06293261 — intervention group
Intervention type: DRUG
Intervention: Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg
Description: Experimental only, not included active and placebo comparator
Study NCT01439893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Study NCT00314171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension
Description: One drop in the study eye(s) twice daily for 12 months
Study NCT00314171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)
Description: One drop in the study eye(s) twice daily for 12 months
Study NCT02236130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional block
Description: Single shot peripheral nerve block
Study NCT02236130 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General Anesthesia with O2/N2O/Sevoflurane
Study NCT02236130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: General Anesthesia with O2/N2O/Sevoflurane
Study NCT02236130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetic Ropivacaine
Description: 0.5% Ropivacaine
Study NCT02236130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids Morphine
Description: Morphine
Study NCT02236130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids Morphine
Description: Morphine
Study NCT02236130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral pain medication Acetaminophen with Hydrocodone
Description: Acetaminophen with Hydrocodone
Study NCT02236130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral pain medication Acetaminophen with Hydrocodone
Description: Acetaminophen with Hydrocodone
Study NCT02353130 — intervention group
Intervention type: DRUG
Intervention: Memantine-XR
Description: Participants will begin with 7mg Memantine XR® daily for a minimum of one week before increasing to an optimal dose of 14 mg daily. It is suggested that participants be titrated to the optimal dose by week 2 so that they may remain on 14mg for at least 6 weeks. Morning dosing is suggested, but can be flexible.
Study NCT00675649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 148 / Golimumab
Description: 100 mg sc injection every 4 weeks from week 0 to week 20
Study NCT00675649 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo sc injection every 4 weeks from week 0 to week 20
Study NCT04493450 — intervention group
Intervention type: OTHER
Intervention: Documentation of cancer treatment side effects
Description: Standardized documentation of occurred side effects
Study NCT03312062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Rolling Exercise
Description: Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets.
Study NCT01434342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Patch
Description: Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, \& 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
Study NCT01572649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Study NCT01572649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection~Route of administration: subcutaneous
Study NCT01107002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer group
Description: Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
Study NCT00617448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diathermy haemorrhoidectomy under espinal anesthesia
Description: For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan).For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
Study NCT00617448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diathermy haemorrhoidectomy under local anesthesia
Description: For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan). For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine \[20 mL, 7.5 mg/mL\] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
Study NCT00617448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure haemorrhoidetomy under spinal anestesia
Description: For surgery: ligasure haemorrhoidectomy For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
Study NCT05929742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early rehabilitation
Description: Five 60-minute sessions per week, was prescribed by a rehabilitation physician and performed by physical, occupational, and speech therapists from 3 to 6 days after admission.
Study NCT03559543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocoxin-Viusid
Description: An oral solution of Oncoxin® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT up to 3 weeks after finishing the treatment.~The treatment with Oncoxin®-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously for approximately 29 weeks from the patient's inclusion in the study.
Study NCT00968955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local infiltration with ropivacaine 0,2% (150 ML)
Study NCT00968955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Local infiltration with ropivacaine 0,2% (150 ML)